Literature DB >> 1503895

Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

H Timmer-Bosscha1, N H Mulder, E G de Vries.   

Abstract

In this review an inventory is made of agents used to circumvent cis-diamminedichloroplatinum(II) (CDDP) resistance in vitro and in vivo. Agents that affect CDDP accumulation and membrane related systems, cytoplasmic defense mechanisms, as well as DNA accessibility and repair are reviewed. In resistant cell lines that have decreased accumulation, this can be restored by hyperthermic treatment. With or without effects on accumulation compounds that affect cell signal transduction often increase CDDP cytotoxicity. Calcium channel blockers and calmodulin inhibitors do not seem to be uniformly good modulators of CDDP resistance. For transduction modulators as well as cellular calcium affecting agents mechanisms are mainly unclear or controversial. Glutathione appears, with the now available agents, to be the most promising target for modulation of cytoplasmic defense mechanisms. At the nuclear level the inhibition of DNA repair related enzymes as well as the use of modified nucleosides to interfere with repair is studied in various cell lines. Results with these agents suggest opportunities for clinically feasible cytotoxicity modulation. DNA accessibility could in vitro be affected, but seems to be an unreliable target for modulation. Whenever possible the resistance mechanism affected and the mode of action of the modulator are discussed. As an alternative for modulation another method of overcoming CDDP resistance namely the application of CDDP analogues is considered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503895      PMCID: PMC1977827          DOI: 10.1038/bjc.1992.249

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  115 in total

1.  Phenotypic reversion of cisplatin resistance in human cells accompanies reduced host cell reactivation of damaged plasmid.

Authors:  C C Chao; Y L Lee; S Lin-Chao
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

2.  In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.

Authors:  G Chen; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells.

Authors:  K B Tan; M R Mattern; R A Boyce; P S Schein
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 4.  Resistance to platinum compounds: mechanisms and beyond.

Authors:  S L Kelley; M Rozencweig
Journal:  Eur J Cancer Clin Oncol       Date:  1989-08

5.  Metallothionein induction in mouse tissues by cis-dichlorodiammineplatinum(II) and its hydrolysis products.

Authors:  P G Farnworth; B L Hillcoat; I A Roos
Journal:  Chem Biol Interact       Date:  1989       Impact factor: 5.192

6.  Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.

Authors:  E J Katz; J S Vick; K M Kling; P A Andrews; S B Howell
Journal:  Eur J Cancer       Date:  1990       Impact factor: 10.002

7.  Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).

Authors:  C M Tsai; A F Gazdar; D J Venzon; S M Steinberg; R L Dedrick; J L Mulshine; B S Kramer
Journal:  Cancer Res       Date:  1989-05-01       Impact factor: 12.701

8.  In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).

Authors:  J M Onoda; K K Nelson; J D Taylor; K V Honn
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

9.  Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C.

Authors:  J Hofmann; F Ueberall; L Posch; K Maly; D B Herrmann; H Grunicke
Journal:  Lipids       Date:  1989-04       Impact factor: 1.880

10.  Metronidazole enhances the cytotoxic synergism produced by the combination of 1-beta-arabinofuranosylcytosine and cis-diamminedichloroplatinum.

Authors:  J M Trujillo; L Y Yang; G Gercovich; Y Z Su; J Lee
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

View more
  34 in total

1.  Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.

Authors:  J G Moggs; D E Szymkowski; M Yamada; P Karran; R D Wood
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

2.  The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin.

Authors:  Yongke Lu; Arthur Cederbaum
Journal:  Free Radic Biol Med       Date:  2007-07-06       Impact factor: 7.376

Review 3.  The path for metal complexes to a DNA target.

Authors:  Alexis C Komor; Jacqueline K Barton
Journal:  Chem Commun (Camb)       Date:  2013-05-07       Impact factor: 6.222

4.  Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.

Authors:  Ganna V Kalayda; Bart A J Jansen; Chris Molenaar; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2004-04-08       Impact factor: 3.358

5.  Comparison of the cytotoxic effects of Juniperus sabina and Zataria multiflora extracts with Taxus baccata extract and Cisplatin on normal and cancer cell lines.

Authors:  M Shokrzadeh; M Azadbakht; N Ahangar; H Naderi; S S Saeedi Saravi
Journal:  Pharmacogn Mag       Date:  2010-05-05       Impact factor: 1.085

6.  Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.

Authors:  Z H Siddik; G Thai; M Yoshida; Y P Zhang; A R Khokhar
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Authors:  Jianli Chen; Mahesha Adikari; Rajash Pallai; Hemant K Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-28       Impact factor: 3.333

8.  Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Authors:  H Parekh; H Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells.

Authors:  L Beketic-Oreskovic; M Osmak
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.

Authors:  G Chen; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.